Lifeward Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $21.1M
- Price
- $7.50
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.32%
- Volume
- 5.2K
About
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
Quick stats
Shares outstanding2.8M
Computed float2.8M
Float / shares97.8%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001607962
Websitehttps://golifeward.com
AI Summary
AI-generated1/13
standardbullishearnings
Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth
Lifeward reported Q2 revenue of $6.6 million, up 16% year-over-year, marking its strongest quarter since Q4 2024 driven by growth in ReWalk and AlterG product lines.
The company strengthened its balance sheet to a proforma cash position of approximately $11 million through a strategic financing that raised $5.6 million in July.
Governance changes include the departure of CFO Almog Adar and the stepping down of the Chairman and two directors, while commercial execution was bolstered by a new pilot program with Ottobock Care.
Red flags
- CFO Almog Adar departing effective September 30, 2026
- Chairman Bob Marshall and two directors stepping down from the board
- Gross margin decreased from 44% to 41% year-over-year due to tariffs and FX
- GAAP net loss widened to $11.5 million driven by non-cash warrant and derivative liability charges